SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    IMS Health Web site. Accessed January 16, 2004. URL: www.imshealth.com.
  • 2
    Fraenkel L, Bogardus S, Concato J, Felson D. Does decreasing the likelihood of toxicity make patients more likely to use medications? J Rheumatol 2003; 30: 4438.
  • 3
    O'Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. J Epidemiol Community Health 1990; 44: 24952.
  • 4
    Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic disease? Br J Rheumatol 1990; 29: 2158.
  • 5
    Ascione FJ, Kirscht JP, Shimp LA. An assessment of different components of patient medication knowledge. Med Care 1986; 24: 101828.
  • 6
    Ribeiro V, Blakeley J, Laryea M. Women's knowledge and practices regarding the prevention and treatment of osteoporosis. Health Care Women Int 2000; 21: 34753.
  • 7
    Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; Suppl 26: 1824.
  • 8
    Katz JN, Daltroy LH, Brennan TA, Liang MH. Informed consent and the prescription of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1992; 35: 125763.
  • 9
    O'Cathain A, Walters SJ, Nicholl JP, Thomas KJ, MKirkham M. Use of evidence based leaflets to promote informed choice in maternity care: randomised controlled trial in everyday practice. BMJ 2002; 324: 6436.
  • 10
    Oliver S, Rajan L, Turner H, Oakley A, Entwistle V, Watt I, et al. Informed choice for users of health services: views on ultrasonography leaflets of women in early pregnancy, midwives, and ultrasonographers. BMJ 1996; 313: 12513.
  • 11
    Stapleton H, Kirkham M, Thomas G. Qualitative study of evidence based leaflets in maternity care. BMJ 2002; 324: 63945.
  • 12
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 13
    Branch VK, Lipsky K, Nieman T, Lipsky PE. Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. Arthritis Care Res 1999; 12: 3705.
  • 14
    Johnson RM. Adaptive conjoint analysis: Sawtooth Software conference proceedings. Sequim (WA): Sawtooth Software; 1987. p. 25365.
  • 15
    Mazur DJ, Hickam DH. Patients' interpretations of probability terms. J Gen Intern Med 1991; 6: 23740.
  • 16
    Altman RD, Moskowitz R. A randomized clinical trial of intra-articular sodium hyaluronate in patients with osteoarthritis of the knee: a summary. Am J Orthop 1999; 28(11 Suppl ): 34.
  • 17
    Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 97887.
  • 18
    Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13: 38395.
  • 19
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al, Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 243847.
  • 20
    Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 242330.
  • 21
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 22
    Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27: 76471.
  • 23
    Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000; 160: 85360.
  • 24
    Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with emphasis on trial methodology. Semin Arthritis Rheum 1997; 26: 75570.
  • 25
    Fraenkel L, Bogardus ST, Wittink DR. Understanding patient preferences for the treatment of lupus nephritis using adaptive conjoint analysis. Med Care 2001; 39: 120316.
  • 26
    Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990; 54: 317.
  • 27
    Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: Armstrong JS, editor. Principles of forecasting: a handbook for researchers and practitioners. Norwell (MA): Kluwer Academic Publishers; 2001.